Dear Editor, AML is occasionally associated with bone marrow (BM) mastocytosis. Differential diagnoses include reactive mast cell (MC) hyperplasia, systemic mastocytosis (SM) with associated clonal hematological non-MC lineage disease, and MC leukemia (MCL) [1] . Myelomastocytic leukemia (MML) is a new classification for AML patients who show an increase in immature and atypical MCs, but who do not fulfill the criteria for MCL or SM [2] [3] [4] [5] [6] [7] . Here, we describe for the first time a case of therapy-related MML, and review key elements of differential diagnosis in patients with myeloid neoplasms and BM mastocytosis [8, 9] .
/L. The peripheral blood smear identified 28% blasts and 40% immature MCs. The BM aspirate smear showed dysplastic features with 46.0% myeloblasts and 22.0% immature atypical MCs (Fig. 1A, 1B The patient declined further chemotherapy or surgical intervention and was transferred to another hospital for supportive care.
Although the overall incidence of MML is unknown, it is clear that the disease is very rare [9] . The first diagnostic criterion of MML is an increase in MC along with myeloblasts in the blood and BM. In this context, morphologically defined subsets of MCs, as described in the consensus proposal and summarized below, can be useful for differential diagnosis: 1) typical mature tissue MCs; 2) atypical type I spindle-shaped MCs; 3) atypical type II MCs, also referred to as promastocytes; and 4) metachromatic blasts [8] . MML is characterized by an increase in the latter two subsets. Histological findings in MML include diffuse spread of MCs, as opposed to SM where MCs form multifocal aggregates. Furthermore, MCs in MML usually lack CD25 and CD2, whereas those in SM aberrantly express CD25 and/or CD2. These findings suggest that the immunohistochemical panel for detecting www.annlabmed.org https://doi.org/10.3343/alm.2017.37.3.282 AML with mastocytosis should at least include CD117, tryptase, CD25 and/or CD2. The presence of KIT D816V mutation excludes the diagnosis of MML [8, 9] .
There are several reasons underscoring the importance of distinguishing MML from other leukemia subtypes with BM mastocytosis. First, it has been suggested that MCs in MML are derived from a malignant clone. A previous study showed that both the tryptase-negative blasts cells and the MCs were found to contain the RUNX1-RUNX1T1 fusion gene [3] . Second, this disease may be mistaken for several other diseases. Without refinement of the diagnostic criteria for MML, hematopathologists might have difficulties in distinguishing between different differential diagnoses in patients with mastocytosis. Third, MML is associated with poor prognosis [9] . This results partially from a complex karyotype and myelodysplasia, as has been reported here as well as in previous patients with MML [7] . Identification of patients at high risk of developing MML can be the starting point for personalized therapy.
In conclusion, although MML poses a diagnostic challenge and is not yet listed in the current WHO classification, a meticulous evaluation of blood and BM smears and a thorough immunohistochemical study of BM trephine specimens facilitate the MML diagnosis.
